Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer Cases
Cheryl T. Lee(The Ohio State University Wexner Medical Center), Thomas Bramley, Amanda Bruno(Bristol-Myers Squibb (United States)), Daniel A. Barocas(Vanderbilt University Medical Center), Ken O’Day, Denise Globe(Allergan (United States)), Michael G. Oefelein(Genesis HealthCare), Danielle Colayco(Allergan (United States))
Cited by 34
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
|The Journal of Urology|2022|462
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
|The Journal of Urology|2023|368